The global psoriatic arthritis (PsA) treatment market, valued at USD 11,973.7 million in 2024, is projected to experience significant growth over the next decade. With a Compound Annual Growth Rate (CAGR) of 7.8%, the market is expected to reach a valuation of USD 25,375.6 million by 2034.
The growing prevalence of psoriatic arthritis, a chronic autoimmune condition that affects the joints and skin, is a primary factor driving the market expansion. Advances in biologic therapies, which offer targeted treatments for PsA, are significantly improving patient outcomes and fueling demand for more effective solutions.
The increasing awareness of PsA, coupled with the rising adoption of advanced therapies, including tumor necrosis factor (TNF) inhibitors and interleukin inhibitors, is expected to further boost the market. The growing focus on personalized treatments and a better understanding of PsA pathophysiology are also contributing to market growth.
As healthcare systems focus on improving management options for chronic inflammatory diseases, the PsA treatment market is set to experience sustained growth, addressing unmet needs for effective and long-term treatments.
Key Growth Drivers
The growth of the PsA treatment market is driven by several factors:
- Rising Prevalence of Psoriatic Arthritis: With approximately 125 million people affected by psoriasis globally, the incidence of psoriatic arthritis is also increasing, leading to higher demand for effective treatments.
- Advancements in Treatment Options: The introduction of new biologics and targeted therapies, such as interleukin inhibitors, has improved clinical outcomes and quality of life for patients.
Market Dynamics
- The market is characterized by a variety of treatment options, including biologics, disease-modifying antirheumatic drugs (DMARDs), and corticosteroids. Biologics are expected to capture a significant share due to their efficacy and safety profile.
- Increased awareness about the importance of early diagnosis and treatment is likely to further drive market growth.
Regional Insights
- North America is expected to dominate the market, accounting for a substantial share due to the presence of major pharmaceutical companies and high adoption rates of advanced therapies.
- The Asia-Pacific region is anticipated to be the fastest-growing market, fueled by improving healthcare infrastructure and rising healthcare spending in countries like China and India.
Competitive Landscape in the Psoriatic Arthritis (PsA) Treatment Market
The development of new drugs remains a priority for players. In addition, collaborative strategies are also part of the vision. Partnerships with public bodies are sought to raise awareness about the disease.
The need for developing novel drug options is evident when looking at an industry giant like Pfizer Inc.
The company also partners with other healthcare sector players for the development of new drugs. Johnson and Johnson also concentrate on new drug development, investing significant amounts into trials.
Recent Developments in the Psoriatic Arthritis (PsA) Treatment Market
In September 2023, Wellmin Health, in collaboration with the non-profit organization Versus Arthritis, launched the Pathway platform. It is a program developed to help patients with arthritis, including psoriatic arthritis.
In February 2024, Biocon Biologics announced that it had reached an agreement with Janssen Biotech Inc. and Johnson & Johnson to commercialize the drug Bmab 1200.
Grab Your Complete Report Instantly
Key Companies in the Psoriatic Arthritis (PsA) Treatment Market
Key companies in the industry include Pfizer Inc., Johnson & Johnson, AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, UCB S.A., Eli Lilly & Co, Novartis AG, Celgene Corporation, and AstraZeneca PLC.
Key Segments of Psoriatic Arthritis (PsA) Treatment Market
By Drug Type:
Based on the drug type, the psoriatic arthritis (PsA) treatment market can be segmented into the following segments: non-steroidal anti-inflammatory drugs, disease modifying anti-rheumatic drugs, and biologics.
Disease-modifying anti-rheumatic drugs can be further separated into corticosteroids, antimalarial, methotrexate, and others. On the other hand, biologics can be bifurcated into TNF inhibitors and interleukin inhibitors.
By Route of Administration:
Based on the route of administration, the psoriatic arthritis (PsA) treatment market can be bifurcated into the following segments: injectable and oral.
By Distribution Channel:
Based on the distribution channel, the psoriatic arthritis (psa) treatment market can be segmented into the following segments: hospital pharmacies, retail pharmacies, and mail-order pharmacies.
By Region:
The sector has been analyzed with the following regions covered: North America, Latin America, Europe, South Asia, East Asia, Oceania, and the Middle East and Africa.
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube